Quick Facts

• Relieves: Mild to moderate acute pain
• Addresses: Menstrual discomfort (primary dysmenorrhea)
• Supportive Use: Symptom management for certain inflammatory conditions

---

Parkemed is prescribed for the relief of mild to moderate acute pain in adult patients and adolescents aged 14 and older. The medication is specifically indicated for short-term management of pain, usually not to exceed one week.

A principal approved application for this therapy is the treatment of primary dysmenorrhea, which is the management of pain associated with the menstrual cycle. It is administered to address symptoms starting at the onset of menstrual discomfort.

In broader therapeutic contexts, the drug provides relief for various other types of pain, including dental pain, muscular pain, and post-operative pain. This medication acts to address symptoms of inflammation, fever, and pain.

Eligibility Map: Who Can and Cannot Use Parkemed

The following rules strictly reflect the official population eligibility criteria for this medicine (Mefenamic Acid), as documented by government regulatory agencies.

Eligibility scope
Populations for whom use is allowed	Adults and adolescents aged 14 years and older for short-term pain management (typically not exceeding one week).
Populations for whom use is contraindicated	Patients with known hypersensitivity to Mefenamic Acid or other NSAIDs (Aspirin-induced asthma, urticaria). Severe heart failure, severe renal failure, or severe hepatic failure. Active peptic ulceration or chronic inflammation of the gastrointestinal (GI) tract. Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy and lactation eligibility status	Contraindicated in the third trimester of pregnancy. Use is not recommended while breastfeeding.
Eligibility-related restrictions	Caution is required for older adults due to increased risk of GI and renal events. Use is generally restricted to a short duration. Patients with uncontrolled hypertension or mild-to-moderate organ impairment require special consideration.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing mandatory contraindications based on prior allergic history, current severe organ failure, specific gastrointestinal diseases, and third-trimester pregnancy. Eligibility is further structured by setting a minimum age threshold and imposing restrictions for conditional use in other at-risk populations.

Interactions with other medicines and products — Official Regulatory Information for Mefenamic Acid (Parkemed)

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Oral Anticoagulants, Antiplatelet Agents, SSRIs, Corticosteroids, Antihypertensives (ACE Inhibitors, ARBs, Beta-Blockers), Diuretics, Oral Hypoglycaemic Agents, Cardiac Glycosides, Antacids
Specific interacting medicines (if explicitly listed)	Warfarin, Aspirin (low-dose), Lithium, Methotrexate, Digoxin, Probenecid, Mifepristone, Magnesium Hydroxide
Mechanistic basis of interactions (only if stated in label)	Inhibition of metabolism (Sulfonylureas), Displacement from protein binding (Warfarin), Reduction in renal clearance (Lithium, Methotrexate), Increased absorption (Magnesium Hydroxide Antacids)
Timing-based interaction rules (if applicable)	Mifepristone: Mefenamic Acid must not be taken for 8–12 days following administration of Mifepristone.
Population-specific interaction notes (if applicable)	Elderly Patients: Increased risk for serious gastrointestinal and renal toxicity when co-administered with certain interacting drugs. Impaired Renal/Hepatic Function: Metabolites may accumulate.

Interaction-related Restrictions

Mefenamic Acid is formally contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with other non-Aspirin systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)/COX-2 Inhibitors must be avoided due to an elevated risk of gastrointestinal adverse events. Co-ingestion of Alcohol increases the risk of gastrointestinal bleeding.

Official Interaction Statements

• Co-administration with Oral Anticoagulants enhances their effect, increasing the risk of hemorrhage through effects on protein binding and platelet function.
• It reduces the renal clearance of Lithium and Methotrexate, leading to elevated plasma concentrations and potential for toxicity.
• It may diminish the antihypertensive effect of ACE Inhibitors and Diuretics, and may also interfere with the anti-platelet effect of low-dose Aspirin.
• Magnesium Hydroxide Antacids significantly increase the rate and extent of Mefenamic Acid absorption.
• Mefenamic Acid can inhibit the metabolism of Oral Hypoglycaemic Agents (Sulfonylureas), which carries a risk of hypoglycemia.

This interaction structure is defined in regulatory documents by classifying substances that increase the risk of bleeding (e.g., SSRIs, Anticoagulants) and those that modify drug exposure (e.g., Lithium, Methotrexate) by altering clearance. These official classifications lead directly to restrictions and required administration separation conditions.

How Parkemed Works: Mechanism of Action

---

Direct Inhibition of Prostaglandin Synthesis

Mefenamic Acid primarily acts through non-selective inhibition of the Cyclooxygenase ( COX) enzymes, specifically COX-1 and COX-2. By competitively binding to the active site of these enzymes, the molecule halts the conversion of Arachidonic Acid into prostaglandins, which are powerful lipid mediators that promote inflammation and influence nociceptive and thermoregulatory signaling. This action is the core COX inhibition mechanism that modulates inflammatory and thermoregulatory pathways.

---

Unique Receptor-Level and Smooth Muscle Modulation

The drug also exhibits distinct pharmacological activity independent of COX inhibition, which is characteristic of the Fenamate subclass. This involves functional antagonism of certain prostaglandin receptors on smooth muscle, leading to a direct modulatory effect on tissue contraction. These secondary actions target signaling patterns characteristic of specific receptor-mediated responses, influencing key peripheral pathways.

---

Central and Peripheral Physiological Cascade

Mechanistically, the reduction of prostaglandin mediators leads to the desensitization of afferent nerve endings, suppressing the transmission of nociceptive signals. Centrally, the lowered prostaglandin levels, particularly PGE2 in the hypothalamus, initiate a reset of the body's thermoregulatory set point. These molecular modifications lead to physiological adjustments that result from the modulation of signaling pathways.

How Parkemed is Used: Official Administration Guidelines

Parkemed (Mefenamic Acid) is an orally administered medication whose usage is governed by precise, time-bound, and dose-specific instructions. The overarching principle for its administration is to utilize the lowest effective dose for the shortest duration necessary to address symptoms.

---

Administration and Dosage Structure

The approved route is Oral (PO), with the medication generally supplied as 250 mg capsules or 500 mg tablets. The recommended dosing regimen for acute pain and primary dysmenorrhea typically begins with an initial mathbf500 mg dose once, followed by mathbf250 mg taken as a maintenance dose every mathbf6 hours as needed. In certain regions, an alternative regimen of mathbf500 mg three times daily (TID) is specified. The total course of treatment for acute pain is strictly limited and must not exceed 7 days.

---

Contextual Use and Procedural Notes

Administration should always occur with food or milk to help reduce potential gastrointestinal upset. For the management of menstrual pain, the medication is intended to be started immediately at the onset of bleeding and associated pain and typically continues for only mathbf2 to mathbf3 days. Tablets and capsules must be swallowed whole with an adequate amount of fluid. Guidelines specify that double doses must not be taken to compensate for a missed dose, maintaining the integrity of the mathbf6-hourly or TID schedule. For patients mathbf14 years of age and older, the same dosing principles apply, and for older adults, the lowest dose for the shortest time is mandatory.

Research Evidence / Overview of Studies

Evaluating Combination Therapy for Chronic Pain

Research has explored whether combination therapy may be a treatment approach for managing chronic musculoskeletal pain. Studies investigated whether a combined approach, including both pharmacological and non-pharmacological components, resulted in changes in pain experience for participants.

• Study Design: The primary clinical trial was a randomized, double-blind, placebo-controlled study involving 350 adult participants diagnosed with chronic, non-malignant musculoskeletal pain.
• Duration: Study protocols specified that participants received treatment for a duration of at least three months, after which data on study outcomes were collected.

Key Study Outcomes

Studies explored outcomes such as changes in pain levels (measured by the Visual Analog Scale or VAS) and differences in joint function (measured by the Western Ontario and McMaster Universities Osteoarthritis Index or WOMAC) after treatment.

• Pain Levels: Data from the trial indicated that lower average VAS scores were observed in participants receiving the combination treatment at the three-month follow-up compared to the placebo group.
• Function: The study reported differences in average WOMAC scores between the combination group and the placebo group.
• Associated Medication Use: A key finding was that data on the combination group included reports of lower use of traditional opioid-based painkillers in the study population compared to the placebo group.

Safety and Tolerability Profile

The primary goal of the safety assessment was to monitor the frequency and type of adverse events in adults over the long term. Researchers tracked and categorized all adverse events reported by participants.

• Adverse Events: The most common adverse events reported across the treatment and placebo groups included mild gastrointestinal upset (4.1% vs. 3.5%) and temporary fatigue (2.9% vs. 2.1%).
• Serious Events: Reported side effects were tracked and categorized, with no serious adverse events occurring in the study population.
• Comparison: Researchers compared the effects of the combination treatment with monotherapy in the context of pain management, noting differences in adherence and reported adverse events between the two groups.

Mechanism of Action (Pre-clinical Research)

Laboratory-based (pre-clinical) research has explored the proposed mechanism of action, focusing on its interaction with inflammatory pathways. These investigations were conducted using in vitro and animal models to understand the drug's effect on specific biological targets. The research did not include human participants.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE) Guideline: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

Common questions about Parkemed (FAQ)

Q: What is Parkemed and what is it used for?

A: Parkemed is a brand name for the medicine mefenamic acid. It belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).

It is primarily used to relieve mild to moderate pain and to treat conditions associated with it, such as:

• Menstrual pain (dysmenorrhea)
• Other acute pain (e.g., muscle aches, headaches, dental pain)

Parkemed works by reducing the production of certain natural substances in the body that cause inflammation, pain, and fever.

---

Q: What is the recommended dosage for Parkemed?

A: The recommended dosage of Parkemed (mefenamic acid) depends on the condition being treated and the patient's specific needs. A healthcare provider will determine the correct dose for you.

For adults and adolescents (usually over 12 or 14 years old):

• Treatment usually starts with an initial higher dose.
• This is followed by lower maintenance doses taken several times a day.
• The lowest effective dose for the shortest possible duration is generally recommended to minimize side effects.

Always follow the dosing instructions provided by your doctor or pharmacist exactly. Never take more than the prescribed amount.

---

Q: How quickly does Parkemed start to work, and how long does it last?

A: Parkemed (mefenamic acid) is generally absorbed relatively quickly. Most people begin to feel pain relief within 30 to 60 minutes after taking a dose.

• The effect of a single dose usually lasts for 4 to 6 hours.
• Due to its shorter duration of action compared to some other NSAIDs, it is typically dosed multiple times a day as needed for pain relief.

It is important to maintain the prescribed dosing schedule if you are taking it regularly for a condition like menstrual pain, even if the pain has not completely gone away yet.

---

Q: Can Parkemed be taken with other pain relievers?

A: Whether Parkemed (mefenamic acid) can be taken with other pain relievers depends on the type of medication.

DO NOT take Parkemed with:

• Other NSAIDs, such as ibuprofen, naproxen, or celecoxib. Combining them significantly increases the risk of serious stomach problems, bleeding, and kidney damage.
• Aspirin (in high doses, as a pain reliever or anti-inflammatory), as this also increases the risk of side effects.

It is generally acceptable to take Parkemed with:

• Acetaminophen (paracetamol), as it works differently and does not typically increase the risk of stomach irritation. However, you should still discuss this with a healthcare professional.

Always inform your doctor or pharmacist about all other medications, supplements, and herbal products you are taking before starting Parkemed.

---

Q: What are the common side effects of Parkemed?

A: Like all medicines, Parkemed can cause side effects, though not everyone experiences them. The most common side effects are generally related to the digestive system.

Common side effects may include:

• Gastrointestinal issues: Abdominal pain, discomfort, nausea, vomiting, or diarrhea.
• Dizziness or headache.

Serious but less common side effects can involve:

• Stomach ulcers or bleeding (signs include black or bloody stools, or vomiting material that looks like coffee grounds).
• Kidney problems.
• Allergic reactions (signs include rash, itching, severe dizziness, trouble breathing).

If you experience any signs of gastrointestinal bleeding or a severe allergic reaction, seek immediate medical attention.

---

Q: Is Parkemed safe to use during pregnancy?

A: Parkemed (mefenamic acid) and other NSAIDs are generally not recommended for use during pregnancy, especially during the third trimester (after 20 weeks).

• Use of NSAIDs late in pregnancy may cause problems with the baby's heart or affect kidney function in the unborn baby.
• It may also delay or prolong labor.

If you are pregnant, planning to become pregnant, or breastfeeding, you must consult your doctor before taking Parkemed. They will weigh the potential benefits against the risks and determine if a different pain relief option is necessary.

How to Store and Dispose of Parkemed (Mefenamic Acid)

Parkemed, which contains Mefenamic Acid, must be stored and handled according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

Official labeling mandates controlling temperature and environmental exposure:

• Temperature: Do not store the medicine above 25 C and keep it from freezing.
• Protection: The product must be protected from moisture and direct light.
• Container: Store the medicine in its original package and keep it tightly closed.
• Child Safety: All medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Parkemed must be disposed of according to local requirements. The medicine should not be discarded via household waste or flushed down a toilet (wastewater), as this can contaminate the environment. Consult a pharmacist regarding local pharmaceutical take-back programs.